Laboratory of Technical Medical Sciences, Department of Biomedical Science for Health, University of Milano, Milan, Italy.
J Clin Gastroenterol. 2012 Oct;46 Suppl:S56-63. doi: 10.1097/MCG.0b013e318265ef38.
To evaluate cytokine stimulation with 3 strains of Lactobacillus salivarius in vitro and to assess changes in intestinal microflora and clinical improvements in adults with atopic dermatitis (AD) induced by the strain showing the best immunomodulatory features.
AD is a common skin disease in children and adults. It is characterized by chronic inflammation, eczema, and increasing intestinal permeability. Various studies have shown that patients with AD presented some modifications in the intestinal microbiota composition; as a result, intestinal microflora is thought to have a pivotal role in this disease.
Thirty-eight patients aged from 18 to 46 years with moderate/severe AD were recruited. Subjects were randomized in a double-blind placebo-controlled study to receive active treatment with L. salivarius LS01: probiotic (n=19) or placebo (n=19). Cytokine production was determined by means of specific quantitative enzyme-linked immunosorbent assays. Intestinal bacterial groups were quantified using conventional culture techniques, whereas L. salivarius LS01 was identified using polymerase chain reaction and pulse field gel electrophoresis.
L. salivarius LS01 showed the best immunomodulatory features and it was chosen for the second phase of the study. AD subjects showed a reduction in their SCORAD score after probiotic treatment and a significant decrease in the staphylococci load compared with the placebo group. Moreover, L. salivarius LS01 showed the ability to reduce the production of Th2 cytokines, maintaining the production of Th1 cytokines stable.
Treatment with the L. salivarius LS01 strain seems to positively modify clinical and immunologic status and dermatology life quality in a group of adults affected by moderate/severe AD, leading to a rebalancing of altered intestinal microbiota.
评估 3 种唾液乳杆菌在体外对细胞因子的刺激作用，并评估具有最佳免疫调节特性的菌株在诱导特应性皮炎（AD）成人的肠道菌群变化和临床改善。
AD 是一种常见的儿童和成人皮肤病。其特征为慢性炎症、湿疹和肠道通透性增加。多项研究表明，AD 患者的肠道微生物群组成存在一些改变；因此，肠道微生物群被认为在这种疾病中具有关键作用。
招募了 38 名年龄在 18 至 46 岁之间的中重度 AD 患者。受试者被随机分配到双盲安慰剂对照研究中，分别接受唾液乳杆菌 LS01：益生菌（n=19）或安慰剂（n=19）的主动治疗。通过特定的定量酶联免疫吸附测定法来确定细胞因子的产生。使用常规培养技术来定量肠道细菌群，而使用聚合酶链反应和脉冲场凝胶电泳来鉴定唾液乳杆菌 LS01。
唾液乳杆菌 LS01 表现出最佳的免疫调节特性，因此被选为研究的第二阶段。AD 患者在益生菌治疗后 SCORAD 评分降低，与安慰剂组相比葡萄球菌负荷显著降低。此外，LS01 能够减少 Th2 细胞因子的产生，同时维持 Th1 细胞因子的稳定产生。
LS01 菌株的治疗似乎可在一定程度上改善一组中重度 AD 成人的临床和免疫状态以及皮肤病生活质量，并使改变的肠道微生物群重新平衡。
